Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

15 results

Filters applied: . Clear all
Page 1
Long-Term Ivacaftor in People Aged 6 Years and Older with Cystic Fibrosis with Ivacaftor-Responsive Mutations.
Pilewski JM, De Boeck K, Nick JA, Tian S, DeSouza C, Higgins M, Moss RB. Pilewski JM, et al. Among authors: moss rb. Pulm Ther. 2020 Dec;6(2):303-313. doi: 10.1007/s41030-020-00129-2. Epub 2020 Sep 23. Pulm Ther. 2020. PMID: 32965659 Free PMC article.
Initially approved for people with CF (pwCF) with G551D-CFTR gating mutations, ivacaftor demonstrated clinical benefit in pwCF with other gating mutations and certain residual function mutations, including R117H-CFTR, in clinical studies. We evaluated the long-term safety …
Initially approved for people with CF (pwCF) with G551D-CFTR gating mutations, ivacaftor demonstrated clinical benefit in pwCF with other ga …
Assessment of safety and efficacy of long-term treatment with combination lumacaftor and ivacaftor therapy in patients with cystic fibrosis homozygous for the F508del-CFTR mutation (PROGRESS): a phase 3, extension study.
Konstan MW, McKone EF, Moss RB, Marigowda G, Tian S, Waltz D, Huang X, Lubarsky B, Rubin J, Millar SJ, Pasta DJ, Mayer-Hamblett N, Goss CH, Morgan W, Sawicki GS. Konstan MW, et al. Among authors: moss rb. Lancet Respir Med. 2017 Feb;5(2):107-118. doi: 10.1016/S2213-2600(16)30427-1. Epub 2016 Dec 21. Lancet Respir Med. 2017. PMID: 28011037 Clinical Trial.
BACKGROUND: The 24-week safety and efficacy of lumacaftor/ivacaftor combination therapy was shown in two randomised controlled trials (RCTs)-TRAFFIC and TRANSPORT-in patients with cystic fibrosis who were aged 12 years or older and homozygous for the F508del-CFTR mutation. We aim …
BACKGROUND: The 24-week safety and efficacy of lumacaftor/ivacaftor combination therapy was shown in two randomised controlled trials (RCTs) …
Long-term treatment with oral N-acetylcysteine: affects lung function but not sputum inflammation in cystic fibrosis subjects. A phase II randomized placebo-controlled trial.
Conrad C, Lymp J, Thompson V, Dunn C, Davies Z, Chatfield B, Nichols D, Clancy J, Vender R, Egan ME, Quittell L, Michelson P, Antony V, Spahr J, Rubenstein RC, Moss RB, Herzenberg LA, Goss CH, Tirouvanziam R. Conrad C, et al. Among authors: moss rb. J Cyst Fibros. 2015 Mar;14(2):219-27. doi: 10.1016/j.jcf.2014.08.008. Epub 2014 Sep 13. J Cyst Fibros. 2015. PMID: 25228446 Free article. Clinical Trial.
Long term effects of denufosol tetrasodium in patients with cystic fibrosis.
Ratjen F, Durham T, Navratil T, Schaberg A, Accurso FJ, Wainwright C, Barnes M, Moss RB; TIGER-2 Study Investigator Group. Ratjen F, et al. Among authors: moss rb. J Cyst Fibros. 2012 Dec;11(6):539-49. doi: 10.1016/j.jcf.2012.05.003. Epub 2012 Jun 8. J Cyst Fibros. 2012. PMID: 22682898 Free article. Clinical Trial.
Fungi and allergic lower respiratory tract diseases.
Knutsen AP, Bush RK, Demain JG, Denning DW, Dixit A, Fairs A, Greenberger PA, Kariuki B, Kita H, Kurup VP, Moss RB, Niven RM, Pashley CH, Slavin RG, Vijay HM, Wardlaw AJ. Knutsen AP, et al. Among authors: moss rb. J Allergy Clin Immunol. 2012 Feb;129(2):280-91; quiz 292-3. doi: 10.1016/j.jaci.2011.12.970. J Allergy Clin Immunol. 2012. PMID: 22284927 Review.
The characteristics of ABPM include severe asthma, eosinophilia, markedly increased total IgE and specific IgE levels, bronchiectasis, and mold colonization of the airways. The term severe asthma associated with fungal sensitization (SAFS) has been coined to illustrate the …
The characteristics of ABPM include severe asthma, eosinophilia, markedly increased total IgE and specific IgE levels, bronchiectasis, and m …
Results of a phase IIa study of VX-809, an investigational CFTR corrector compound, in subjects with cystic fibrosis homozygous for the F508del-CFTR mutation.
Clancy JP, Rowe SM, Accurso FJ, Aitken ML, Amin RS, Ashlock MA, Ballmann M, Boyle MP, Bronsveld I, Campbell PW, De Boeck K, Donaldson SH, Dorkin HL, Dunitz JM, Durie PR, Jain M, Leonard A, McCoy KS, Moss RB, Pilewski JM, Rosenbluth DB, Rubenstein RC, Schechter MS, Botfield M, Ordoñez CL, Spencer-Green GT, Vernillet L, Wisseh S, Yen K, Konstan MW. Clancy JP, et al. Among authors: moss rb. Thorax. 2012 Jan;67(1):12-8. doi: 10.1136/thoraxjnl-2011-200393. Epub 2011 Aug 8. Thorax. 2012. PMID: 21825083 Free PMC article. Clinical Trial.
Additional data are needed to determine how improvements detected in CFTR function secondary to VX-809 in the sweat gland relate to those measurable in the respiratory tract and to long-term measures of clinical benefit. CLINICAL TRIAL NUMBER: NCT00865904....
Additional data are needed to determine how improvements detected in CFTR function secondary to VX-809 in the sweat gland relate to those me …
High-dose oral N-acetylcysteine, a glutathione prodrug, modulates inflammation in cystic fibrosis.
Tirouvanziam R, Conrad CK, Bottiglieri T, Herzenberg LA, Moss RB, Herzenberg LA. Tirouvanziam R, et al. Among authors: moss rb. Proc Natl Acad Sci U S A. 2006 Mar 21;103(12):4628-33. doi: 10.1073/pnas.0511304103. Epub 2006 Mar 13. Proc Natl Acad Sci U S A. 2006. PMID: 16537378 Free PMC article. Clinical Trial.
Pulmonary function measures were not improved, as expected with short-term treatment. After excluding data from subjects without baseline airway inflammation, positive treatment effects were more pronounced and included decreased sputum IL-8 levels (P = 0.032). ...
Pulmonary function measures were not improved, as expected with short-term treatment. After excluding data from subjects without base …
Long-term benefits of inhaled tobramycin in adolescent patients with cystic fibrosis.
Moss RB. Moss RB. Chest. 2002 Jan;121(1):55-63. doi: 10.1378/chest.121.1.55. Chest. 2002. PMID: 11796432 Clinical Trial.
STUDY OBJECTIVE: To determine the effect of long-term suppression of Pseudomonas aeruginosa on lung function and other clinical end points in adolescent patients with cystic fibrosis (CF). ...CONCLUSIONS: TSI treatment improved pulmonary function and weight gain in adolesc …
STUDY OBJECTIVE: To determine the effect of long-term suppression of Pseudomonas aeruginosa on lung function and other clinical end p …
Long-term follow-up of HIV-1-infected Thai patients immunized with Remune monotherapy.
Sukeepaisarncharoen W, Churdboonchart V, Kulpradist S, Isarangkura Na Ayudthya B, Rugpao S, Chandeying V, Sirawaraporn W, Carlo D, Moss RB. Sukeepaisarncharoen W, et al. Among authors: moss rb. HIV Clin Trials. 2001 Sep-Oct;2(5):391-8. doi: 10.1310/Q5XX-A5CH-XTB9-FN33. HIV Clin Trials. 2001. PMID: 11673813 Clinical Trial.
PURPOSE: The purpose of this 2-year follow-up study was to investigate the long-term effect of Remune as monotherapy for HIV-1 infection. BACKGROUND: Participants previously enrolled in the phase II double-blind, randomized, adjuvant-controlled study of the HIV-1 Immunogen …
PURPOSE: The purpose of this 2-year follow-up study was to investigate the long-term effect of Remune as monotherapy for HIV-1 infect …
Administration of aerosolized antibiotics in cystic fibrosis patients.
Moss RB. Moss RB. Chest. 2001 Sep;120(3 Suppl):107S-113S. doi: 10.1378/chest.120.3_suppl.107s. Chest. 2001. PMID: 11555564
A 96-week series of clinical studies including 520 patients, aged > or = 6 years, with moderate-to-severe CF has evaluated the long-term safety and effectiveness of this formulation. Patients received tobramycin solution for inhalation (TSI) or placebo, which was admini …
A 96-week series of clinical studies including 520 patients, aged > or = 6 years, with moderate-to-severe CF has evaluated the long-te …
15 results